Amgen, Inc. (AMGN) Plans Quarterly Dividend of $1.45
Amgen, Inc. (NASDAQ:AMGN) declared a quarterly dividend on Friday, December 7th, RTT News reports. Investors of record on Friday, February 15th will be given a dividend of 1.45 per share by the medical research company on Friday, March 8th. This represents a $5.80 annualized dividend and a yield of 3.03%. This is a boost from Amgen’s previous quarterly dividend of $1.32.
Amgen has increased its dividend by an average of 23.5% annually over the last three years and has increased its dividend every year for the last 7 years. Amgen has a dividend payout ratio of 37.8% meaning its dividend is sufficiently covered by earnings. Analysts expect Amgen to earn $14.37 per share next year, which means the company should continue to be able to cover its $5.28 annual dividend with an expected future payout ratio of 36.7%.
NASDAQ AMGN opened at $191.44 on Friday. Amgen has a 1-year low of $163.31 and a 1-year high of $210.19. The company has a market capitalization of $126.81 billion, a P/E ratio of 15.22, a PEG ratio of 2.07 and a beta of 1.41. The company has a quick ratio of 2.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.05.
In other news, SVP Cynthia M. Patton sold 1,777 shares of Amgen stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total value of $360,517.76. Following the completion of the sale, the senior vice president now owns 23,090 shares of the company’s stock, valued at $4,684,499.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.19% of the stock is owned by insiders.
AMGN has been the subject of several recent research reports. Cann reissued a “buy” rating and set a $224.00 price target on shares of Amgen in a research report on Monday, October 1st. Royal Bank of Canada reissued a “neutral” rating and set a $193.00 price target on shares of Amgen in a research report on Monday, September 10th. Goldman Sachs Group reissued a “buy” rating and set a $229.00 price target on shares of Amgen in a research report on Friday, October 12th. Oppenheimer reissued a “buy” rating and set a $224.00 price target on shares of Amgen in a research report on Tuesday, August 28th. Finally, Jefferies Financial Group set a $220.00 price target on Amgen and gave the stock a “buy” rating in a research report on Monday, October 8th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Amgen has a consensus rating of “Hold” and a consensus target price of $205.68.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Article: Balanced Fund
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.